Somewhat Positive Press Coverage Somewhat Unlikely to Affect Cempra (MLNT) Share Price
Media headlines about Cempra (NASDAQ:MLNT) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cempra earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.5774497055094 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne (finance.yahoo.com)
- Head-To-Head Comparison: Cempra (MLNT) and Its Peers (americanbankingnews.com)
- New Haven Biotech Goes Public (conntact.com)
Shares of Cempra (MLNT) opened at $12.35 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.49 and a current ratio of 11.49. Cempra has a 52 week low of $10.25 and a 52 week high of $41.00.
A number of brokerages have issued reports on MLNT. Jefferies Group LLC reissued a “neutral” rating on shares of Cempra in a research note on Thursday, October 26th. Zacks Investment Research lowered shares of Cempra from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Robert W. Baird raised shares of Cempra from an “underperform” rating to a “neutral” rating and set a $2.00 target price for the company in a research note on Wednesday, November 1st. ValuEngine raised shares of Cempra from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Finally, Roth Capital lowered shares of Cempra from a “buy” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $4.00 in a research note on Thursday, August 10th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $6.05.
TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cempra-mlnt-share-price.html.
Cempra Company Profile
Melinta Therapeutics, Inc, formerly Cempra, Inc, is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Stock Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related stocks with our FREE daily email newsletter.